GlassScriptPhysician profile
Chelsi Brink
NPI 1396094199
$1,340.36
in general payments reported to CMS, 2019-2025
22 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $186 · 2023: $154 · 2024: $389 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $427.88 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $111.79 | 2021-2024 | Zepbound, Jardiance, Mounjaro |
| Mylan Specialty L.P. | $98.63 | 2021-2024 | Yupelri |
| Abbvie INC. | $97.07 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.00 | 2022-2024 | |
| Vanda Pharmaceuticals INC. | $62.38 | 2021 | |
| Lundbeck LLC | $59.26 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $48.74 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $44.76 | 2024 | Airsupra, Breztri, Farxiga |
| Sunovion Pharmaceuticals INC. | $42.36 | 2021 | |
| Pfizer INC. | $35.98 | 2022-2025 | |
| Exact Sciences Corporation | $32.99 | 2024-2025 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $30.32 | 2021 | |
| Medtronic, INC. | $27.31 | 2025 | Minimed 780g |
| Verona Pharma, INC. | $21.58 | 2025 | Ohtuvayre |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cmp Pharma, INC. | $20.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.36 | 2021 | |
| Seqirus USA INC | $18.74 | 2025 | Fluad, Flucelvax |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.85 | 2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.46 | 2022 | |
| Glaxosmithkline, LLC. | $13.25 | 2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsi Brink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.